Analysis Of The Effect Of EGFR-TKI And Platinum Containing Chemotherapy On The Preoperative Stage Of ? B Lung Adenocarcinoma In Qinghai

Objective: To study the difference between TKI and chemotherapy in the treatment of stage IIIBadenocarcinoma with EGFR sensitive mutation.It can provide theoretical basis for TKI treatment and chemotherapy in clinical application and selection of treatment scheme.To sum up the experience of new adjuvant treatment before operation of adenocarcinoma in our hospital,and to provide reference for further improving the level of diagnosis and treatment in our hospital.Methods: from September 2018 to September 2019,EGFR positive patients with stage IIIB adenocarcinoma in Affiliated Hospital of Qinghai University were collected as research objects.The subjects were divided into two groups: the observation group and the control group.The observation group was treated with gefitinib(250mg / D)orally for 4-8 weeks,followed by surgery for 3-6 weeks;the control group was treated with neoadjuvant chemotherapy for 2-4 cycles,followed by surgery for 3-6 weeks,followed by pemetrexed + cisplatin.To explore and analyze the descending stage of lung cancer in the two groups.The T stage of lung cancer was reduced according to WTO standard.Record the original data and make a conclusion through statistical data processing.Results:The decrease rate of T stage was 62.50% in the observation group,31.25% in the N stage,64.56% in the control group and 21.52% in the N stage.The difference between the observation group and the control group was not statisticallysignificant(P > 0.05).The resection rate of the observation group and the control group was 50.00% after the new auxiliary target treatment,and the hand was in the control group The surgical resection rate was 49.37%,and there was no significant difference between the observation group and the control group(P > 0.05);the operation condition of the observation group and the control group: the ratio of intraoperative blood loss,operation time,postoperative thoracic drainage tube retention time,postoperative average hospital stay time and other indicators had no significant difference(P > 0.05);but in the 24-hour postoperative thoracic drainage flow,The difference was statistically significant(P < 0.05).There was no significant difference in postoperative complications between the observation group and the control group(P < 0.05).Conclusions: gefitinib is an effective new adjuvant targeting therapy for EGFR positive IIIB lung adenocarcinoma patients,which can increase the survival rate without increasing the difficulty of operation and postoperative complications.At present,target therapy is not widely used in clinical treatment,and the number of samples is small.It is not sure that the effect of preoperative new adjuvant target therapy is equivalent to that of preoperative new adjuvant chemotherapy.In the future research work,basic research and large-scale clinical trials are needed to answer.